Nautilus Biotechnology (NASDAQ:NAUT) Stock Rating Raised to “Hold” at Zacks Research

Nautilus Biotechnology (NASDAQ:NAUT) was upgraded by research analysts at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Roth Capital started coverage on Nautilus Biotechnology in a report on Tuesday. They set a “buy” rating and a $3.50 target price for the company. Finally, Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.83.

Nautilus Biotechnology Stock Up 10.6%

NAUT opened at $1.57 on Wednesday. Nautilus Biotechnology has a 52 week low of $0.82 and a 52 week high of $4.31. The firm has a 50-day simple moving average of $1.01 and a two-hundred day simple moving average of $2.01. The company has a market capitalization of $199.78 million, a PE ratio of -3.49 and a beta of 0.73.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, sell-side analysts expect that Nautilus Biotechnology will post -0.52 earnings per share for the current year.

Institutional Trading of Nautilus Biotechnology

A number of large investors have recently made changes to their positions in NAUT. TD Waterhouse Canada Inc. lifted its position in Nautilus Biotechnology by 1,500.0% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after acquiring an additional 15,000 shares during the period. CTC Alternative Strategies Ltd. purchased a new stake in Nautilus Biotechnology during the first quarter worth about $48,000. Callan Family Office LLC purchased a new position in shares of Nautilus Biotechnology during the 2nd quarter worth about $49,000. Squarepoint Ops LLC purchased a new stake in shares of Nautilus Biotechnology during the 2nd quarter valued at $63,000. Finally, AXQ Capital LP purchased a new position in shares of Nautilus Biotechnology in the 2nd quarter worth about $64,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.